Agios Pharmaceuticals AGIO

$31.59 -0.17 (-0.54%)

Valuation

Market cap: 1,899,566,000
Revenue TTM: $54,030,000
Net income TTM: $-412,780,000
P/E (trailing): 0.00
P/E (forward): —
Profit margin: -763.98%
Debt to equity: 0.00

Trading

Volume: 371,300
Avg volume: 1,152,406
Day's range: $30.81 – $31.97
Shares out: 59,810,000
Stochastic %K: 72%
Beta: 0.66
Analysts: Moderate Buy
Price target: $44.50

Price

Company profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 617 649 8600
Website: https://www.agios.com
Address: 88 Sidney Street, Cambridge, United States

Latest news

No headlines yet.

Stocktwits

Merlintrader Nov 10, 6:59 AM

$AGIO Agios (AGIO): mitapivat revenue $55.4M, cash $907.0M Weekly catalysts newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.

0 replies

stu4 Nov 7, 3:10 PM

$AGIO BFD @Gurujoe the whole mgmt team are public money blood suckers , white collar welfare,no scientific qualifications. Biotech misfits , laid off from other failing or defunct biotechs . A seller in the scientific role, when the FDA sends back , oct 9 , 2026 , an issue ( must be resolved ) and she, Sarah G , sells shares on the news Scum bags exist here or in the real world , RATS Keep up your hard work , Joe , for they will continue to disappoint you here at AGIOS

0 replies

stu4 Nov 7, 3:01 PM

$AGIO no one ….watchers has fallen by 100 on 2900 , hahaha Why ?? Mgmt are LIARS….they fit the glove of TRUMPERS They have since Schenkien lied to the street in 2015 and that doctrine lives on in spirit . Sarah G , a loser, heading up their science is no Chris Bowden , and she sells shares after the FDA notified them of issues Oct 9, 2026 and they responded Oct 19, 2026 , NOW calling it an amendment ( and she knew the FDA date of Nov 1 was in jeopardy YOU WANT TO GET IN ON THIS BOTCHED BUNCH OF MISFITS ???? @Ruey …. Activity is DISGUST , like Bellevue who sold last Nov 2025 and took their 40M loss in one day

0 replies

Ruey Nov 7, 12:40 PM

$AGIO Quite a bit of activity lately. I'm curious who's been paying attention

0 replies

BiotechCatalystCalendar Nov 5, 7:17 PM

$AGIO: $55.4M Q3 mitapivat revenue, 619 cumulative completed AQVESME start forms, ~75% on therapy at 6 months. Feb. 1 FDA date next. https://biotechcatalystcalendar.substack.com/p/start-here-how-to-get-the-most-out

0 replies

Merlintrader Nov 5, 4:10 PM

$AGIO : Agios Pharmaceuticals Q3 2026 (reported Nov 5): Mitapivat net revenue $55.4M vs $12.9M a year earlier ($48.7M U.S., $6.6M ex-U.S.); Net loss $65.0M, $(1.09) per share; Cash and marketable securities $907.0M at Sept 30; Sickle-cell FDA goal date February 1, 2027; labeling discussions under way. Questions worth checking: When is the next AGIO stock catalyst? How much cash does Agios have, and how long will it last? Is mitapivat FDA approved for sickle cell disease? Answers, primary sources and downloadable PDF report in our hub: https://www.merlintrader.com/agios-pharmaceuticals-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=agio_hubpdf_nov26 Not investment advice.

0 replies

Stonky_Mcprofitface Nov 5, 3:00 PM

$AGIO he’s not wrong

0 replies

d_risk Nov 5, 2:46 PM

$AGIO - Agios Pharmaceuticals Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +104.9% above peer average (24,516 vs 11,964 across 655 peers). Agios disclosed that its response to an FDA request about whether a risk evaluation and mitigation strategy (REMS) is needed for mitapivat in sickle cell disease constituted a major amendment. The supplemental application’s FDA review goal date was extended to February 1, 2027. #RegulatoryChallenges #IntellectualPropertyRisks #InternationalExpansion #PricingPressure #Pharmaceuticals 🟢 Added 🟠 Removed https://d-risk.ai/AGIO/10-Q/2026-11-05

1 replies